ImmunityBio, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 10-Q, Quarterly reportAug 4 →InsidersNo open-market buys. 2 insiders sold $4.6M, all 9 sales on a 10b5-1 plan.→HoldersBlackRock 3.2%State Street 2.0%Vanguard Portfolio 1.7%→Financing →PeersClosest companies: IOVA, FATE, PYXS→Ideas1 idea posted by members→
From the filings
Figures
- Revenue
- $165.8Mlast 12 months
- Net income
- −$992.5Mlast 12 months
- Operating cash flow
- −$294.4Mlast 12 months
- Cash and equivalents
- $75.7Mat the last balance sheet
- Total debt
- $884,000at the last balance sheet
- Shares outstanding
- 1.05B shareson issue